10.5061/DRYAD.FJ6Q573WF
Parapanov, Roumen
0000-0001-8101-7813
University Hospital of Lausanne
Wang, Xingyu
University Hospital of Lausanne
Debonneville, Anne
0000-0003-2259-8595
University Hospital of Lausanne
Lugrin, Jérôme
University Hospital of Lausanne
Wang, Yabo
University Hospital of Lausanne
Abdelnour, Etienne
University Hospital of Lausanne
Gonzalez, Michel
University Hospital of Lausanne
Perentes, Jean
University Hospital of Lausanne
Gronchi, Fabrizio
University Hospital of Lausanne
Eckert, Philippe
University Hospital of Lausanne
Piquilloud, Lise Piquilloud
University Hospital of Lausanne
Letovanec, Igor
University Hospital of Lausanne
Krueger, Thorsten
University Hospital of Lausanne
Liaudet, Lucas
0000-0003-2670-4930
University Hospital of Lausanne
Treatment with 3-aminobenzamide during ex vivo lung perfusion of damaged
rat lungs reduces graft injury and dysfunction after transplantation
Dryad
dataset
2021
FOS: Medical and health sciences
Swiss National Science Foundation
https://ror.org/00yjd3n13
310030 172975
Swiss National Science Foundation
https://ror.org/00yjd3n13
310030 162629
2022-01-06T00:00:00Z
2022-01-06T00:00:00Z
en
https://doi.org/10.1111/ajt.15695
12235 bytes
5
CC0 1.0 Universal (CC0 1.0) Public Domain Dedication
Ex vivo lung perfusion (EVLP) with pharmacological reconditioning may
increase donor lung utilization for transplantation (LTx).
3-Aminobenzamide (3-AB), an inhibitor of poly (ADP-ribose) polymerase
(PARP), reduces ex vivo lung injury in rat lungs damaged by warm ischemia
(WI). Here we determined the effects of 3-AB reconditioning on graft
outcome after LTx. Three groups of donor lungs were studied: Control
(Ctrl): 1 hour WI + 3 hours cold ischemia (CI) + LTx; EVLP: 1 hour
WI + 3 hours EVLP + LTx; EVLP + 3-AB: 1 hour WI + 3 hours EVLP + 3-AB
(1 mg.mL−1) + LTx. Two hours after LTx, we determined lung graft
compliance, edema, histology, neutrophil counts in bronchoalveolar lavage
(BAL), mRNA levels of adhesion molecules within the graft, as well as
concentrations of interleukin-6 and 10 (IL-6, IL-10) in BAL and plasma.
3-AB reconditioning during EVLP improved compliance and reduced lung
edema, neutrophil infiltration, and the expression of adhesion molecules
within the transplanted lungs. 3-AB also attenuated the IL-6/IL-10 ratio
in BAL and plasma, supporting an improved balance between pro- and
anti-inflammatory mediators. Thus, 3-AB reconditioning during EVLP of rat
lung grafts damaged by WI markedly reduces inflammation, edema, and
physiological deterioration after LTx, supporting the use of PARP
inhibitors for the rehabilitation of damaged lungs during EVLP.